Incidence of acute phase adverse events following denosumab or intravenous bisphosphonates: Results from a randomized, controlled phase II study in patients with breast cancer and bone metastases

Cynthia Campbell-Baird, Allan Lipton, Makan Sarkeshik, Haijun Ma, Susie Jun

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Acute phase reactions, defined as mild to moderate flu-like symptoms, are associated with intravenous bisphosphonate (IV BP) initiation. In this report, we compared the incidence of flu-like syndrome and other acute phase adverse events (AEs) occurring 3 days or 4 weeks after initiation of subcutaneous denosumab (every 4 weeks [30, 120, or 180 mg] or every 12 weeks [60 or 80 mg]) or IV BP (every 4 weeks) in patients with advanced breast cancer and bone metastases naïve to IV BPs enrolled in a randomized, phase II, partially blinded study. Denosumab-treated patients experienced fewer acute phase AEs than those receiving IV BPs both within the first 3 days (denosumab 9%, IV BP 33%; P = 0.0001) and 4 weeks following treatment initiation (denosumab 27%, IV BP 49%; P = 0.0059). Phase III trials of denosumab in cancer and bone metastases are ongoing.

Original languageEnglish (US)
Pages (from-to)85-89
Number of pages5
JournalCommunity Oncology
Volume7
Issue number2
DOIs
StatePublished - Jan 1 2010

Fingerprint

Bone Neoplasms
Diphosphonates
Breast Neoplasms
Neoplasm Metastasis
Incidence
Acute-Phase Reaction
Denosumab

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology

Cite this

@article{bd9456e0e92242e1a4e76d21bfcce1d1,
title = "Incidence of acute phase adverse events following denosumab or intravenous bisphosphonates: Results from a randomized, controlled phase II study in patients with breast cancer and bone metastases",
abstract = "Acute phase reactions, defined as mild to moderate flu-like symptoms, are associated with intravenous bisphosphonate (IV BP) initiation. In this report, we compared the incidence of flu-like syndrome and other acute phase adverse events (AEs) occurring 3 days or 4 weeks after initiation of subcutaneous denosumab (every 4 weeks [30, 120, or 180 mg] or every 12 weeks [60 or 80 mg]) or IV BP (every 4 weeks) in patients with advanced breast cancer and bone metastases na{\"i}ve to IV BPs enrolled in a randomized, phase II, partially blinded study. Denosumab-treated patients experienced fewer acute phase AEs than those receiving IV BPs both within the first 3 days (denosumab 9{\%}, IV BP 33{\%}; P = 0.0001) and 4 weeks following treatment initiation (denosumab 27{\%}, IV BP 49{\%}; P = 0.0059). Phase III trials of denosumab in cancer and bone metastases are ongoing.",
author = "Cynthia Campbell-Baird and Allan Lipton and Makan Sarkeshik and Haijun Ma and Susie Jun",
year = "2010",
month = "1",
day = "1",
doi = "10.1016/S1548-5315(11)70560-5",
language = "English (US)",
volume = "7",
pages = "85--89",
journal = "Community Oncology",
issn = "1548-5315",
publisher = "BioLink Communications",
number = "2",

}

Incidence of acute phase adverse events following denosumab or intravenous bisphosphonates : Results from a randomized, controlled phase II study in patients with breast cancer and bone metastases. / Campbell-Baird, Cynthia; Lipton, Allan; Sarkeshik, Makan; Ma, Haijun; Jun, Susie.

In: Community Oncology, Vol. 7, No. 2, 01.01.2010, p. 85-89.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Incidence of acute phase adverse events following denosumab or intravenous bisphosphonates

T2 - Results from a randomized, controlled phase II study in patients with breast cancer and bone metastases

AU - Campbell-Baird, Cynthia

AU - Lipton, Allan

AU - Sarkeshik, Makan

AU - Ma, Haijun

AU - Jun, Susie

PY - 2010/1/1

Y1 - 2010/1/1

N2 - Acute phase reactions, defined as mild to moderate flu-like symptoms, are associated with intravenous bisphosphonate (IV BP) initiation. In this report, we compared the incidence of flu-like syndrome and other acute phase adverse events (AEs) occurring 3 days or 4 weeks after initiation of subcutaneous denosumab (every 4 weeks [30, 120, or 180 mg] or every 12 weeks [60 or 80 mg]) or IV BP (every 4 weeks) in patients with advanced breast cancer and bone metastases naïve to IV BPs enrolled in a randomized, phase II, partially blinded study. Denosumab-treated patients experienced fewer acute phase AEs than those receiving IV BPs both within the first 3 days (denosumab 9%, IV BP 33%; P = 0.0001) and 4 weeks following treatment initiation (denosumab 27%, IV BP 49%; P = 0.0059). Phase III trials of denosumab in cancer and bone metastases are ongoing.

AB - Acute phase reactions, defined as mild to moderate flu-like symptoms, are associated with intravenous bisphosphonate (IV BP) initiation. In this report, we compared the incidence of flu-like syndrome and other acute phase adverse events (AEs) occurring 3 days or 4 weeks after initiation of subcutaneous denosumab (every 4 weeks [30, 120, or 180 mg] or every 12 weeks [60 or 80 mg]) or IV BP (every 4 weeks) in patients with advanced breast cancer and bone metastases naïve to IV BPs enrolled in a randomized, phase II, partially blinded study. Denosumab-treated patients experienced fewer acute phase AEs than those receiving IV BPs both within the first 3 days (denosumab 9%, IV BP 33%; P = 0.0001) and 4 weeks following treatment initiation (denosumab 27%, IV BP 49%; P = 0.0059). Phase III trials of denosumab in cancer and bone metastases are ongoing.

UR - http://www.scopus.com/inward/record.url?scp=77649222170&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77649222170&partnerID=8YFLogxK

U2 - 10.1016/S1548-5315(11)70560-5

DO - 10.1016/S1548-5315(11)70560-5

M3 - Article

AN - SCOPUS:77649222170

VL - 7

SP - 85

EP - 89

JO - Community Oncology

JF - Community Oncology

SN - 1548-5315

IS - 2

ER -